Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
Harvard University · Massachusetts General Hospital · +20 more institutions
Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Sacituzumab govitecan (SG), a first-in-class anti–trophoblast cell surface antigen 2 (Trop-2) antibody-drug conjugate, demonstrated superior efficacy over single-agent chemotherapy (treatment of physician's choice [TPC]) in patients with metastatic triple-negative breast cancer (mTNBC) in the…
Citation impact
- FWCI
- 53.51
- Percentile
- 100%
- References
- 24
Authors
20Topics & keywords
- Medicine
- Clinical endpoint
- Hazard ratio
- Internal medicine
- Oncology
- Metastatic breast cancer
- Quartile
- Phases of clinical research
- Good health and well-being
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- GSGilead Sciences
- CCelgene
- MKMerck KGaA
- LLLes Laboratories Pierre Fabre
- RHRadius Health
- DTDenali Therapeutics
- RMRevolution Medicines
- RTRelay Therapeutics
- PBPuma Biotechnology
- MMacroGenics
- GTG1 Therapeutics
- SSeagen
- EEisai
- APAstellas Pharma
- SServier
- MGMenarini Group
- GGenentech
- DSDaiichi Sankyo Europe